Perifosine and Sorafenib Combination Induces Mitochondrial Cell Death and Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
Overview
Authors
Affiliations
The effects of the Akt inhibitor perifosine and the RAF/MEK/ERK inhibitor sorafenib were investigated using two CD30(+)Hodgkin lymphoma cell lines (L-540 and HDLM-2) and the CD30(-)HD-MyZ histiocytic cell line. The combined perifosine/sorafenib treatment significantly inhibited mitogen-activated protein kinase and Akt phosphorylation in two of the three cell lines. Profiling of the responsive cell lines revealed that perifosine/sorafenib decreased the amplitude of transcriptional signatures that are associated with the cell cycle, DNA replication and cell death. Tribbles homolog 3 (TRIB3) was identified as the main mediator of the in vitro and in vivo antitumor activity of perifosine/sorafenib. Combined treatment compared with single agents significantly suppressed cell growth (40-80%, P<0.001), induced severe mitochondrial dysfunction and necroptotic cell death (up to 70%, P<0.0001) in a synergistic manner. Furthermore, in vivo xenograft studies demonstrated a significant reduction in tumor burden (P<0.0001), an increased survival time (81 vs 45 days, P<0.0001), an increased apoptosis (2- to 2.5-fold, P<0.0001) and necrosis (2- to 8-fold, P<0.0001) in perifosine/sorafenib-treated animals compared with mice receiving single agents. These data provide a rationale for clinical trials using perifosine/sorafenib combination.
Zhuang T, Wang S, Yu X, He X, Guo H, Ou C Biomark Res. 2024; 12(1):88.
PMID: 39183323 PMC: 11346179. DOI: 10.1186/s40364-024-00639-0.
Establishing a novel and sensitive assay for bioactivity determination of anti-CD25 antibodies.
Duan M, Yu C, Yang Y, Fu Z, Liu C, Du J Heliyon. 2023; 9(6):e17401.
PMID: 37416689 PMC: 10320283. DOI: 10.1016/j.heliyon.2023.e17401.
Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.
Adamova B, rihova K, Pokludova J, Benes P, Smarda J, Navratilova J J Cell Mol Med. 2022; 27(1):76-88.
PMID: 36523175 PMC: 9806293. DOI: 10.1111/jcmm.17636.
Aoun R, El Hadi C, Tahtouh R, El Habre R, Hilal G Cancer Cell Int. 2022; 22(1):123.
PMID: 35305635 PMC: 8933915. DOI: 10.1186/s12935-022-02542-w.
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.
Vendramini E, Bomben R, Pozzo F, Bittolo T, Tissino E, Gattei V Cancers (Basel). 2022; 14(3).
PMID: 35158933 PMC: 8833570. DOI: 10.3390/cancers14030666.